Recurrent severe hypophosphatemia following intravenous iron administration

Hypophosphatemia postintravenous iron is frequent but under‐recognized. If prolonged or recurrent, it can cause osteomalacia. The likely mechanisms are direct toxicity to proximal tubular cells causing phosphate wasting, elevated Fibroblast growth factor‐23 (FGF‐23), and reduced 1,25‐dihydroxyvitami...

Descripción completa

Detalles Bibliográficos
Autores principales: Nataatmadja, Melissa Stephanie, Francis, Ross
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7044372/
https://www.ncbi.nlm.nih.gov/pubmed/32128165
http://dx.doi.org/10.1002/ccr3.2595
_version_ 1783501556777222144
author Nataatmadja, Melissa Stephanie
Francis, Ross
author_facet Nataatmadja, Melissa Stephanie
Francis, Ross
author_sort Nataatmadja, Melissa Stephanie
collection PubMed
description Hypophosphatemia postintravenous iron is frequent but under‐recognized. If prolonged or recurrent, it can cause osteomalacia. The likely mechanisms are direct toxicity to proximal tubular cells causing phosphate wasting, elevated Fibroblast growth factor‐23 (FGF‐23), and reduced 1,25‐dihydroxyvitamin D (1,25(OH)(2)D). Hypophosphatemia may be severe and persist for months, necessitating phosphate replacement until normalization of serum levels occurs.
format Online
Article
Text
id pubmed-7044372
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-70443722020-03-03 Recurrent severe hypophosphatemia following intravenous iron administration Nataatmadja, Melissa Stephanie Francis, Ross Clin Case Rep Case Reports Hypophosphatemia postintravenous iron is frequent but under‐recognized. If prolonged or recurrent, it can cause osteomalacia. The likely mechanisms are direct toxicity to proximal tubular cells causing phosphate wasting, elevated Fibroblast growth factor‐23 (FGF‐23), and reduced 1,25‐dihydroxyvitamin D (1,25(OH)(2)D). Hypophosphatemia may be severe and persist for months, necessitating phosphate replacement until normalization of serum levels occurs. John Wiley and Sons Inc. 2020-01-09 /pmc/articles/PMC7044372/ /pubmed/32128165 http://dx.doi.org/10.1002/ccr3.2595 Text en © 2019 The Authors. Clinical Case Reports published by John Wiley & Sons Ltd. This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Reports
Nataatmadja, Melissa Stephanie
Francis, Ross
Recurrent severe hypophosphatemia following intravenous iron administration
title Recurrent severe hypophosphatemia following intravenous iron administration
title_full Recurrent severe hypophosphatemia following intravenous iron administration
title_fullStr Recurrent severe hypophosphatemia following intravenous iron administration
title_full_unstemmed Recurrent severe hypophosphatemia following intravenous iron administration
title_short Recurrent severe hypophosphatemia following intravenous iron administration
title_sort recurrent severe hypophosphatemia following intravenous iron administration
topic Case Reports
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7044372/
https://www.ncbi.nlm.nih.gov/pubmed/32128165
http://dx.doi.org/10.1002/ccr3.2595
work_keys_str_mv AT nataatmadjamelissastephanie recurrentseverehypophosphatemiafollowingintravenousironadministration
AT francisross recurrentseverehypophosphatemiafollowingintravenousironadministration

Ejemplares similares